Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Eton Pharmaceuticals Inc has a consensus price target of $24.75 based on the ratings of 4 analysts. The high is $35 issued by HC Wainwright & Co. on May 29, 2025. The low is $10 issued by HC Wainwright & Co. on December 11, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., B. Riley Securities, and Craig-Hallum on May 29, 2025, May 16, 2025, and May 14, 2025, respectively. With an average price target of $29.67 between HC Wainwright & Co., B. Riley Securities, and Craig-Hallum, there's an implied 76.17% upside for Eton Pharmaceuticals Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/29/2025 | Buy Now | 107.84% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $33 → $35 | Maintains | Buy | Get Alert |
05/16/2025 | Buy Now | 54.39% | B. Riley Securities | Madison El-Saadi39% | $24 → $26 | Reiterates | Buy → Buy | Get Alert |
05/14/2025 | Buy Now | 66.27% | Craig-Hallum | Chase Knickerbocker59% | $26 → $28 | Maintains | Buy | Get Alert |
03/19/2025 | Buy Now | 54.39% | Craig-Hallum | Chase Knickerbocker59% | $23 → $26 | Maintains | Buy | Get Alert |
03/19/2025 | Buy Now | 42.52% | B. Riley Securities | Madison El-Saadi39% | $21 → $24 | Reiterates | Buy → Buy | Get Alert |
03/19/2025 | Buy Now | 95.96% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $33 → $33 | Reiterates | Buy → Buy | Get Alert |
01/23/2025 | Buy Now | 95.96% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $17 → $33 | Maintains | Buy | Get Alert |
01/10/2025 | Buy Now | 24.7% | B. Riley Securities | Madison El-Saadi39% | → $21 | Initiates | → Buy | Get Alert |
01/08/2025 | Buy Now | 6.89% | Craig-Hallum | Chase Knickerbocker59% | $15 → $18 | Maintains | Buy | Get Alert |
01/06/2025 | Buy Now | 0.95% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $15 → $17 | Maintains | Buy | Get Alert |
11/26/2024 | Buy Now | -10.93% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $11 → $15 | Reiterates | Buy → Buy | Get Alert |
11/13/2024 | Buy Now | -34.68% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
10/28/2024 | Buy Now | -10.93% | Craig-Hallum | Chase Knickerbocker59% | $10 → $15 | Maintains | Buy | Get Alert |
10/04/2024 | Buy Now | -40.62% | Craig-Hallum | Chase Knickerbocker59% | $8 → $10 | Maintains | Buy | Get Alert |
10/04/2024 | Buy Now | -34.68% | HC Wainwright & Co. | Swayampakula Ramakanth53% | $9 → $11 | Maintains | Buy | Get Alert |
09/04/2024 | Buy Now | -46.56% | HC Wainwright & Co. | Swayampakula Ramakanth53% | → $9 | Assumes | → Buy | Get Alert |
05/06/2024 | Buy Now | -52.49% | Craig-Hallum | Chase Knickerbocker59% | → $8 | Initiates | → Buy | Get Alert |
12/11/2023 | Buy Now | -40.62% | HC Wainwright & Co. | Raghuram Selvaraju44% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | Buy Now | -40.62% | HC Wainwright & Co. | Raghuram Selvaraju44% | $9 → $10 | Maintains | Buy | Get Alert |
07/03/2023 | Buy Now | -46.56% | HC Wainwright & Co. | Raghuram Selvaraju44% | $10 → $9 | Maintains | Buy | Get Alert |
03/21/2023 | Buy Now | -40.62% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $10 | Reiterates | → Buy | Get Alert |
09/26/2022 | Buy Now | -40.62% | HC Wainwright & Co. | Raghuram Selvaraju44% | $9 → $10 | Maintains | Buy | Get Alert |
07/25/2022 | Buy Now | -46.56% | HC Wainwright & Co. | Raghuram Selvaraju44% | $11 → $9 | Maintains | Buy | Get Alert |
The latest price target for Eton Pharmaceuticals (NASDAQ:ETON) was reported by HC Wainwright & Co. on May 29, 2025. The analyst firm set a price target for $35.00 expecting ETON to rise to within 12 months (a possible 107.84% upside). 16 analyst firms have reported ratings in the last year.
The latest analyst rating for Eton Pharmaceuticals (NASDAQ:ETON) was provided by HC Wainwright & Co., and Eton Pharmaceuticals maintained their buy rating.
There is no last upgrade for Eton Pharmaceuticals
There is no last downgrade for Eton Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eton Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eton Pharmaceuticals was filed on May 29, 2025 so you should expect the next rating to be made available sometime around May 29, 2026.
While ratings are subjective and will change, the latest Eton Pharmaceuticals (ETON) rating was a maintained with a price target of $33.00 to $35.00. The current price Eton Pharmaceuticals (ETON) is trading at is $16.84, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.